IDP-121

IDP-121 is a first-in-class stapled peptide specifically designed to directly target and inhibit the c-MYC protein, a key oncogene frequently activated in various cancers. Its mechanism of action involves disrupting the c-MYC/MAX complex, promoting the degradation of c-MYC protein, and consequently decreasing its DNA-binding activity. Developed by IDP Pharma, IDP-121 has demonstrated significant efficacy in preclinical models of lung cancer and hematological tumors, including multiple myeloma, diffuse large B cell lymphoma, high-grade B cell lymphoma, and chronic lymphocytic leukemia. The drug exhibits favorable drug-like properties, such as high stability in plasma, no significant hepatic metabolism, and strong plasma protein binding. It has successfully completed GLP toxicology studies without evidence of major systemic toxicity, paving the way for its clinical development.